🔴 Gossamer Bio is trading 5% down in pre-market alongside biotech ETF XBI's 3.65% pre-market drop

Gossamer Bio is trading at $8.00, down 5.09%, with biotech-sector weakness a possible factor.

• Biotech ETF XBI was down 3.65% pre-market, while supplied broad-index figures showed only mixed, modest moves.
• No new company-specific announcement explaining the October 20 pre-market decline was identified. Recent coverage concerns the seralutinib FDA review path and predates the move.
• No pre-market volume or activity-level data was provided.